key in my opinion to curis is the update on cudc-907 trial data from ph1. pi3k + hdac inhibitor. third cycle of cohort 1 will be completed by tomorrow and we should have more insight. also iap inhibitor which was created by genentech will be another near term driver with asco oral abstract and start of phase 2 soon. good luck!